# Winhe Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/winhe-pharma

- Industry: Pharmaceuticals
- Headquarters: Yuxi, China
- Website: www.winhey.com.cn
- Total disclosed funding: $13M
- Latest round: Series C (Jul 1, 2015)
- Investors on record: 4

## About

Established in 2008 and based in Yuxi, China, Winhe Pharma is a pharmaceutical company whose business integrates product research and development, drug production, herb cultivation and sales. The company has a GMP-certified production plant covering an area of more than 100 acres, 6500 acres of original ecological medicinal herbs plantation base, and the R&D center has been recognized as Yunnan Provincial Enterprise Technology Center. In April 2016, it closed a round of strategic investment.

The company is mainly engaged in the research and development, production and sales of natural plant medicines with Panax notoginseng as the main raw material, as well as the plantation business of Panax notoginseng and other Chinese herbal medicines. The products are mainly cardiovascular and cerebrovascular drugs, supplemented by drugs for bruises and injuries, dispelling wind and removing dampness, and tonifying and nourishing blood, mainly including the Haematoxylin series, which consists of Haematoxylin Tablets, Haematoxylin Capsules and other 56 categories.

## Funding rounds

- Series C, Jul 1, 2015, $10M — CITIC Kingview Capital Management, Houyang Capital
- Series B, May 1, 2015, $2.6M — CITIC Kingview Capital Management, New Margin Capital
- Angel, Jun 10, 2010 — GTJA Innovation Investment

## Investors

- GTJA Innovation Investment (https://capitalatlas.ai/funds/gtja-innovation-investment) — Angel
- CITIC Kingview Capital Management (https://capitalatlas.ai/funds/citic-kingview-capital-management) — Series B, Series C
- New Margin Capital (https://capitalatlas.ai/funds/new-margin-capital) — Series B
- Houyang Capital — Series C